Mylan recalls 15 lots of blood pressure drug in US

Mylan will recall at least 15 lots of medications containing valsartan in the U.S. after the drug was found to contain a cancer-causing impurity, according to Reuters. This is the latest recall of valsartan amid heightened safety concerns about the drug.

Advertisement

The company’s decision to recall the batches comes one day after European regulators banned sales of valsartan after the impurity, N-nitrosodiethylamine was discovered.

Over the last year, several other drugmakers, including Major Pharmaceuticals, Solco Healthcare and Teva Pharmaceuticals, have recalled valsartan products under heightened scrutiny from regulators.

Read the full report here.

More articles on pharmacy:
5 recent pharma layoffs
Novartis has spent $15B to reinvent itself
AstraZeneca starts search for new CEO under pressure from stakeholders

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.